I'm LongbridgeAI, I can summarize articles.DSS fell 2.96% on the week to $0.7011, against a 0.08% dip in the S&P 500, underperforming by about 2.88 percentage points. The stock opened lower on Monday before pushing up to $0.7620, saw volume swell to 104,664 shares on Wednesday, hit a weekly high of $0.7698 on Thursday, then gave back gains into Friday’s close at $0.7011. It was a quiet week with no major catalyst, averaging about 71,934 shares a day.
The Week
DSS fell 2.96% on the week to $0.7011, against a 0.08% dip in the S&P 500, underperforming by about 2.88 percentage points. The stock opened lower on Monday before pushing up to $0.7620, saw volume swell to 104,664 shares on Wednesday, hit a weekly high of $0.7698 on Thursday, then gave back gains into Friday’s close at $0.7011. It was a quiet week with no major catalyst, averaging about 71,934 shares a day.
Analyst Ratings
A single broker covers the stock with a buy rating. The consensus stands at strong buy with a target of $3.00, roughly 327.9% above the latest price of $0.7011. Both high and low targets sit at $3.00, leaving little dispersion. Within the commercial printing industry, the rating ranks 6th out of 6 names.
The Week Ahead
The coming week brings a run of US macro data: the Richmond Fed composite index on Tuesday, weekly EIA crude and Cushing crude stockpiles on Wednesday, then initial jobless claims, the current account balance, new home sales and natural gas inventories on Thursday. Among this week’s news, Impact Biomedical filed a Form F-4 to advance its proposed merger with Zoar Ltd., a development to track in the days ahead.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.